Relevant bibliographies by topics / Sucralfato / Journal articles
To see the other types of publications on this topic, follow the link: Sucralfato.

Journal articles on the topic 'Sucralfato'

Author: Grafiati
Published: 4 June 2021
Last updated: 15 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Sucralfato.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ayala Pío, Salomón, David Díaz, Manuel Palomino, Segundo Armas, and Juan Paz. "Efecto Protector de Croton palanostigma y Aloe frente a Injuria Aguda de Mucosa Gástrica inducida por Etanol en Ratas." Anales de la Facultad de Medicina 60, no. 1 (2014): 22. http://dx.doi.org/10.15381/anales.v60i1.4498.

Full text
Abstract:
OBJETIVOS: Evaluar el grado de protección frente a la necrosis de la mucosa gástrica inducida por etanol con Croton palanostigma (Sangre de Grado) y Aloe vera, y compararlo con el de sucralfato y una suspensión de antiácido (AlOH3 +MgOH3+simeticona), en un modelo experimental estandarizado en ratas. MATERIAL Y MÉTODOS: Se evaluó a 56 animales, administrándoles en ayunas uno de 7 pretratamientos: solución salina, C. palanostigma (0,4 ó 0,8 mL/kg), A. vera (7,5 ó 3,2 mL/kg), sucralfato (500 mg/kg) o antiácido. Una hora más tarde, se administró por vía intragástrica 2 mL de etanol al 100%. Se realizó una evaluación cualitativa y cuantitativa, macroscópica y microscópica, de las lesiones gástricas. RESULTADOS: El pretratamiento con C. palanostigma redujo significativamente la aparición de necrosis hemorrágica inducida por etanol, A. vera no presentó efecto protector, mientras que sí lo presentaron el sucralfato, en grado significativo, y el antiacido, en menor grado. CONCLUSIÓN: En nuestras condiciones experimentales, Croton palanostigma presentó un importante efecto protector y potencial terapéutico.
APA, Harvard, Vancouver, ISO, and other styles
2

Palomino, Miriam, Oscar Huamán, Elsa Béjar, Christian Palomino, and Justina Najarro. "Actividad antioxidante y gastroprotectora del extracto hidroalcohólico de hojas de Heliotropum arborescens L, en úlceras inducidas con etanol en estómago de ratas." Anales de la Facultad de Medicina 73 (May 7, 2013): 21. http://dx.doi.org/10.15381/anales.v73i1.2131.

Full text
Abstract:
Objetivos: Evaluar la actividad antioxidante y protectora del extracto hidroalcohólico de Heliotropium arborescens L ‘cayaraja’ sobre la mucosa gástrica en úlceras inducidas en ratas. Evaluar el efecto antioxidante. Evaluar el grado de protección del extracto en estómago de ratas Diseño: Descriptivo transversal Institución: Facultad de Medicina UNMSM. material biológico: 48 ratas machos y 30 ratones. Intervenciones: Para evaluar el efecto protector se administró fármacos y extracto a 6 grupos: I control; II ranitidina; III sucralfato; IV, V y VI extracto 200, 400 y 600 mg/kg vía oral; luego, se realizó laparatomía abdominal y análisis bioquímico correspondiente. Principales medidas de resultados: Marcha fitoquímica, IC50. Evaluación histopatológica del estómago: úlceras/ individuo. Análisis bioquímico: moco y GS-NP: mL/g de tejido. Resultados: El extracto de cayaraja presentó efecto protector dosis dependiente. El tratamiento con ranitidina no produjo protección frente al etanol; el tratamiento con sucralfato produjo buen efecto citoprotector. Se observó gastritis erosiva en las ratas tratadas con extracto 200 y 400 mg/kg; con 600 mg/kg y sucralfato no se presentaron erosiones gástricas. La actividad antioxidante IC50 del extracto fue 2,62. Conclusiones: La cayaraja presentó actividad gastroprotectora y actividad antioxidante.
APA, Harvard, Vancouver, ISO, and other styles
3

Ayala Pío, Salomón, Hilda Jurupe, David Díaz, et al. "Efecto protector de látex desecado y fracción alcaloidea de Croton palanostigma frente a injuria de mucosa gástrica inducida por etanol en ratas." Anales de la Facultad de Medicina 62, no. 4 (2014): 317. http://dx.doi.org/10.15381/anales.v62i4.4205.

Full text
Abstract:
OBJETIVOS: Evaluar el grado de protección de necrosis de la mucosa gástrica por etanol, con látex desecado y fracciones alcaloideas de C. palanostigma, en un modelo experimental estandarizado en ratas. Evaluar toxicidad subcrónica. MATERIAL Y MÉTODOS: Se evaluó 60 animales, administrándoles uno de 6 pretratamientos: solución salina, látex desecado de C. palanostigma 120 mg/kg, fracción alcaloidea de C. palanostigma 20 mg/kg, 35 mg/kg y 50 mg/kg y sucralfato 500 mg/kg. Una hora más tarde se aplicó por vía intragástrica 2 mL de etanol al 100%. Se realizó evaluación macroscópica y microscópica de las lesiones gástricas. Se evaluó la toxicidad subcrónica a la dosis de 0,12, 0,40 y 1,20 mL/kg, por el período de 30 días, con estudios bioquímicos e histopatológicos de los órganos. RESULTADOS: El pretratamiento con látex y las fracciones alcaloideas y el sucralfato redujo significativamente la necrosis hemorrágica inducida por el etanol. La toxicidad subcrónica en la dosis mayor mostró riesgo de esteatosis hepática. CONCLUSIÓN: En nuestras condiciones experimentales el C. palanostigma y la taspina presentaron importante efecto protector y potencial terapéutico. En toxicidad subcrónica, la dosis mayor presentó riesgo de esteatosis hepática.
APA, Harvard, Vancouver, ISO, and other styles
4

Sandoval Vegas, Miguel Hernán, Janeth Tenorio Mucha, Aldo Tinco Jayo, Rudi A. Loli Ponce, and Segundo Calderón Pinillos. "Efecto antioxidante y citoprotector del tocosh de Solanum tuberosum ‘papa’ en la mucosa gástrica de animales de experimentación." Anales de la Facultad de Medicina 76, no. 1 (2015): 15. http://dx.doi.org/10.15381/anales.v76i1.11070.

Full text
Abstract:
El tocosh es un producto alimenticio obtenido por una técnica de conservación andina y que tiene propiedades nutritivas y terapéuticas. Objetivo: Demostrar la capacidad antioxidante y el efecto citoprotector del tocosh de Solanum tuberosum ‘papa’ en la mucosa gástrica de animales de experimentación. Diseño: Experimental. Institución: Centro de Investigación de Bioquímica y Nutrición, Facultad de Medicina, Universidad Nacional Mayor de San Marcos, Lima, Perú. Material biológico: Tocosh seco y molido administrado a ratas albinas. Intervenciones: A 6 grupos de ratas albinas machos (200 ± 50 g) se les dividió en: (GI) solución NaCl 0,9%, 10 mL/kg; (GII) etanol al 70% a 10 mL/kg; (GIII, IV y V) Tocosh equivalente a 900 mg/kg, 1 800 mg/kg y 2 700 mg/kg, respectivamente, y (GVI) sucralfato 30 mg/kg. En todos los casos, una hora después se indujo injuria con etanol 70° a 10 mL/kg y por laparotomía abdominal se obtuvo el tejido gástrico. Principales medidas de resultados: Porcentaje de citoprotección gástrica en imagen digitalizada por image analysis software for plant disease quantification y capacidad antioxidante por lipoperoxidación método espectrofotométrico de la reacción de especies reactivas al ácido tiobarbitúrico (TBARS). Resultados: La marcha fitoquímica identificó compuestos fenólicos, alcaloides, triterpenoides y esteroides, azúcares reductores y aminoácidos libres como metabolitos secundarios. Las dosis de 2 700 mg/kg y 900 mg/kg resultaron en 0,72 y 1,81 nmol/g tejido de lipoperoxidación, respectivamente. La dosis de 1 800 mg/kg protegió un 97% del área de la mucosa gástrica, 2 700 mg/kg un 95% y la de 900 mg/kg, 88% (p<0,05). La dosis de 1 800 mg/kg exhibió mejor efecto citoprotector y la de 2 700 mg/kg mejor actividad antioxidante, comparada con sucralfato 30 mg/kg. Conclusiones: El tocosh de Solanum tuberosum ‘papa’ tuvo efecto citoprotector y actividad antioxidante.
APA, Harvard, Vancouver, ISO, and other styles
5

Herencia Reyes, Vilma, Israel Rivera, Lucy E. Correa Lopez, and Jhony A. De La Cruz Vargas. "Efecto gastroprotector de un nutraceutico compuesto por Ocimum micranthum Willd (albahaca silvestre) frente a ulceras gastricas inducidas por etanol en ratas." Revista Peruana de Medicina Integrativa 3, no. 2 (2019): 91. http://dx.doi.org/10.26722/rpmi.2018.32.87.

Full text
Abstract:
Objetivo: Investigar el efecto de los extractos acuosos en infusión y cocimiento de unnutraceutico compuesto de Ocimum micranthum Willd (ISHCATUL®), en un modelo deulcera gástrica inducida con etanol en ratas. Materiales y Métodos: Estudioexperimental. Se distribuyeron 25 ratas machos en cuatro grupos de estudio: 1)Control Negativo (Suero fisiológico 0.9% 1mL/100 g); 2) Control Positivo (Sucralfato500 mg/Kg); 3) Experimental 1 (Cocimiento a dosis 1mL/100 g); y 4) Experimental 2(Infusión a dosis 2mL. /100 g). Adicionalmente se utilizó una rata como blanco, parapoder realizar comparaciones mediante la visualización directa del tejido gástrico. Seindujo ulcera gástrica mediante la administración intragastrica de Etanol absoluto al75% 1 mL/100g. Se realizó una observación directa de características macroscópicascon las que se calculó el índice ulceroso y porcentajes de inhibición de ulceragástrica. Resultados: El grupo de tratamiento 1 y 2 obtuvieron un porcentaje deinhibición de 35.2% y 21.2 %, lo que no fue superior comparado con el 75% obtenidopor el grupo que recibió sucralfato. Conclusión: Se encontraron efectosgastroprotectores en los grupos de estudio que recibieron decocto (a 1 mL/mg) einfusión (a 2mL/mg) de un nutraceutico compuesto de Ocimum micranthum Willd(Albahaca salvaje), en modelos experimentales de inducción de ulcera gástrica poretanol al 75%, que no fueron superiores a los controles positivos.
APA, Harvard, Vancouver, ISO, and other styles
6

Champion, Malcolm C. "Therapeutic Options in the Treatment and Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Ulceration." Canadian Journal of Gastroenterology 4, no. 3 (1990): 113–19. http://dx.doi.org/10.1155/1990/826248.

Full text
Abstract:
This article reviews the current status of H2receptor antagonists, omeprazole, sucralfate and misoprostol as therapeutic options for the prophylaxis and treatment of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal ulceration. The efficacy of the Hz receptor antagonists appears to be restricted to prophylaxis and treatment of NSAID-induced duodenal ulcer disease. Omeprazole may have a place in the future treatment of NSAID-induced gastric ulcers. However, more studies are necessary to examine this drug's efficacy in both the prophylaxis and treatment of NSAID-induced ulceration. Sucralface improves symptoms, but does not appear to have any effect on improving gastric mucosal damage when compared to placebo. It may, however, be useful in the treatment of NSAID-induced duodenal ulcers. Misoprostol is effective in both the prophylaxis and treatment of NSAID-induced gastric ulcers; however, its exact role in the prophylaxis and treatment of NSAlD-induced duodenal ulcers remains to be defined.
APA, Harvard, Vancouver, ISO, and other styles
7

McCullough, Ricky Wayne. "Regulatory Dichotomy of Sucralfate, Its history and the new Bioadhesive polymerized Sucralfate barrier therapy for Oral health, Oncology support and Gastrointestinal disorders." International Journal of Drug Regulatory Affairs 7, no. 3 (2019): 40–47. http://dx.doi.org/10.22270/ijdra.v7i3.343.

Full text
Abstract:
Sucralfate is a biologically inert non-systemically acting compound. It requires polymerization for conversion into its biological active form, polymerized Sucralfate. Should this conversion occur in the body, using processes of the body to effect conversion subsequent to administering a dose, then the administered Sucralfate is a drug, as it enlists bodily functions to enact a chemical change. This form of Sucralfate should be regulated as drug. On the other hand, Sucralfate is manufactured as a polymerized product, requiring no bodily functions to enable its therapeutic effect, then this form of Sucralfate act as a medical device and should be regulated as such. This dichotomy of Sucralfate was first recognized by the US FDA in 2005 that subsequently cleared several polymerized Sucralfate barrier therapies as medical devices.This review covers the history of the regulatory dichotomy or duality of Sucralfate, the biological basis for Sucralfate clinical effects and the regulatory position of several barrier therapies.
APA, Harvard, Vancouver, ISO, and other styles
8

Wallace, John L., Gerald P. Morris, Paul L. Beck, Todd E. Williamson, and Guy R. Gingras. "Effects of sucralfate on gastric prostaglandin and leukotriene synthesis: relationship to protective actions." Canadian Journal of Physiology and Pharmacology 66, no. 5 (1988): 666–70. http://dx.doi.org/10.1139/y88-105.

Full text
Abstract:
The mechanism of the protective actions of sucralfate against ethanol-induced gastric mucosal damage in the rat has been investigated. In particular, the role of prostaglandins as mediators of such protection was assessed. Oral administration of sucralfate at a dose causing a significant reduction of ethanol-induced gastric damage (500 mg/kg) did not significantly alter gastric 6-ketoprostaglandin F1α synthesis. Pretreatment with indomethacin at a dose that inhibited gastric cyclooxygenase activity by an average of 88% did not affect the protective actions of sucralfate. To further investigate the mechanism of action of sucralfate, an ex vivo gastric chamber model was used in which sucralfate could be applied to only one side of the mucosa. Sucralfate did not affect gastric prostaglandin synthesis, but did cause a significant increase in leukotriene C4 synthesis, a fall in transmucosal potential difference, and a significant decrease in gastric myeloperoxidase activity on the side exposed to sucralfate. These observations suggest that sucralfate has an irritant action on the mucosa. The release of mediators in response to such irritation may play an important role in the protective action of sucralfate. The present study supports the hypothesis that prostaglandins do not mediate the protection afforded by exposure to sucralfate.
APA, Harvard, Vancouver, ISO, and other styles
9

Koshariya, Mahim, Abhishek Shitole, Vibhore Agarwal, and S. Dave. "Role of topical Sucralfate in healing of burn wounds." International Surgery Journal 5, no. 9 (2018): 2995. http://dx.doi.org/10.18203/2349-2902.isj20183409.

Full text
Abstract:
Background: Sucralfate is a basic aluminum salt of sucrose octasulphate which was orally taken for prevention and treatment of several gastrointestinal diseases. This study primarily aims to analyze whether sucralfate accelerates wound healing process in burn patients. The incidence of infection & relieve in pain in burn patients was also compared.Methods: This is an observational study carried out in the Department of General Surgery, Hamidia Hospital Bhopal on 50 patients divided into group 1 (sucralfate)and group 2 [a-sucralfate; b-silver sulfadiazine (SSD)]. Demographics, history, physical, and systemic examinations of the patients were recorded.Results: It was observed that sucralfate augments the formation of granulation tissue (in 6-17 days) as compared to SSD (14-22 days). It was noticed that faster healing by re-epithelialization was present in sucralfate group (11-22 days) as compared with SSD group (15-30 days). By the end of 3rd week 50-75% of wound was healed in sucralfate group as compared with 35-50% in SSD group. Incidence of secondary infection was less when topical sucralfate was used (group 1 = 25%; group 2a = 16.6%; group 2b = 66.66%). There was a marked relief in pain and discomfort after sucralfate application as compared to SSD.Conclusions: Using topical sucralfate expedite the burn wound healing process, significantly decreases pain with no local or systemic adverse reactions to the topical application therefore it can be used as an adjunctive or alternative agent in the future. However, multicentric trials with larger sample size are needed to insure the concept.
APA, Harvard, Vancouver, ISO, and other styles
10

Martenson, James A., John W. Bollinger, Jeff A. Sloan, et al. "Sucralfate in the Prevention of Treatment-Induced Diarrhea in Patients Receiving Pelvic Radiation Therapy: A North Central Cancer Treatment Group Phase III Double-Blind Placebo-Controlled Trial." Journal of Clinical Oncology 18, no. 6 (2000): 1239–45. http://dx.doi.org/10.1200/jco.2000.18.6.1239.

Full text
Abstract:
PURPOSE: Randomized studies have suggested that sucralfate is effective in mitigating diarrhea during pelvic radiation therapy (RT). This North Central Cancer Treatment Group study was undertaken to confirm the antidiarrheal effect of sucralfate. Several other measures of bowel function were also assessed.PATIENTS AND METHODS: Patients receiving pelvic RT to a minimum of 45 Gy at 1.7 to 2.1 Gy/d were eligible for the study. Patients were assigned randomly, in double-blind fashion, to receive sucralfate (1.5 g orally every 6 hours) or an identical looking placebo during pelvic RT.RESULTS: One hundred twenty-three patients were randomly assigned and found assessable. Overall, there was no significant difference in patient characteristics between those receiving sucralfate and those receiving placebo. Moderate or worse diarrhea was observed in 53% of patients receiving sucralfate versus 41% of those receiving placebo. Compared with patients receiving placebo, more sucralfate-treated patients reported fecal incontinence (16% v 34%, respectively; P = .04) and need for protective clothing (8% v 23%, respectively; P = .04). The incidence and severity of nausea were worse among those taking sucralfate (P = .03). Analysis of patient-reported symptoms 10 to 12 months after RT showed a nonsignificant trend toward more problems in patients taking sucralfate than in those taking placebo (average, 2.3 v 1.9 problems, respectively; P = .34).CONCLUSION: Sucralfate did not decrease pelvic RT-related bowel toxicity by any of the end points measured and seems to have aggravated some gastrointestinal symptoms.
APA, Harvard, Vancouver, ISO, and other styles
11

Henriksson, R., L. Franzén, and B. Littbrand. "Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer." Journal of Clinical Oncology 10, no. 6 (1992): 969–75. http://dx.doi.org/10.1200/jco.1992.10.6.969.

Full text
Abstract:
PURPOSE Radiotherapy, a cornerstone in the management of pelvic cancer, is accompanied by intestinal reactions. Therefore, we investigated the possible effects of sucralfate, an aluminium hydroxide complex of sulfated sucrose used in the treatment of gastric ulcer, in preventing radiation-induced diarrhea and bowel discomfort in patients treated with curative intention for pelvic cancer with external radiotherapy. PATIENTS AND METHODS The study was double-blind and placebo-controlled and included 70 patients with carcinoma in the prostate or urinary bladder without distant metastases (T1-4No1xMo) and a performance status of greater than or equal to 90% on the Karnofsky scale. Radiotherapy was conventionally delivered with high-energy photons (four-field technique, the total dose 64 Gy, 2 Gy daily, total treatment time 5 to 6 weeks). Dose granules of sucralfate or placebo were dispensed to each patient 2 weeks after radiation started and continued for 6 weeks. All analyses were performed blindly. RESULTS The frequency of defecation and stool consistency were significantly improved by sucralfate. Fourteen patients in the placebo group and three in the sucralfate group required symptomatic therapy with loperamide. One year later, the patients in the sucralfate group displayed significantly less problems with frequency of defecation, mucus, and blood in the stools compared with the placebo group. There was also a lower intake of loperamide and the weight decrease was less pronounced in the sucralfate group. There was no evidence of adverse effects associated with the use of sucralfate. CONCLUSION It is suggested that sucralfate can be of beneficial value in diminishing bowel discomfort during treatment and, most importantly, sucralfate also reduces the late bowel disturbances that follow radiotherapeutic treatment of pelvic malignancies. The earlier proposed mechanisms of action (eg, protection of denuded mucosa, cytoprotective properties, binding bile acids) seem adequate to explain the present effects of sucralfate.
APA, Harvard, Vancouver, ISO, and other styles
12

Quimby, Jessica, and Michael Lappin. "Evaluating Sucralfate as a Phosphate Binder in Normal Cats and Cats with Chronic Kidney Disease." Journal of the American Animal Hospital Association 52, no. 1 (2016): 8–12. http://dx.doi.org/10.5326/jaaha-ms-6213.

Full text
Abstract:
Control of hyperphosphatemia is an important part of the management of chronic kidney disease (CKD). The purpose of this study was to determine the efficacy of sucralfate as a phosphate binder in normal cats and normophosphatemic CKD cats. A 500 mg sucralfate slurry was administered orally q 8 hr for 2 wk, and serum phosphorus, urine fractional excretion of phosphorus, and fecal phosphorus concentrations were measured. In normal cats treated with sucralfate, significant changes in serum phosphorus concentration or urinary excretion of phosphorus were not detected, and vomiting occurred after 14.7% of administrations. Of the five normophosphatemic cats with CKD treated with sucralfate, three experienced clinical decompensation, including vomiting, anorexia, constipation, and increased azotemia. Administration of sucralfate did not result in significant changes in fecal phosphorus concentration in these cats. The effects of sucralfate administration on serum phosphorus concentration and urinary excretion of phosphorus in CKD cats was difficult to determine because of dehydration and worsening azotemia associated with decompensation. Due to side effects and the apparent lack of efficacy of the medication, the study was discontinued. This study was unable to confirm efficacy of this sucralfate formulation as a phosphate binder, and side effects were problematic during the study.
APA, Harvard, Vancouver, ISO, and other styles
13

McGinnis, W. L., C. L. Loprinzi, S. J. Buskirk, et al. "Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis." Journal of Clinical Oncology 15, no. 3 (1997): 1239–43. http://dx.doi.org/10.1200/jco.1997.15.3.1239.

Full text
Abstract:
PURPOSE To determine whether a sucralfate oral solution can prevent/alleviate radiation-induced esophagitis. PATIENTS AND METHODS Patients included on this clinical trial were beginning thoracic radiation therapy to the mediastinum. Following stratification, they were randomized, in a double-blind manner, to receive a sucralfate solution or an identical-appearing placebo solution. Esophagitis was measured by physicians who used standard criteria and also by patients who used short questionnaires completed weekly during the course of the trial. RESULTS A total of 97 assessable patients were entered onto this clinical trial. During the first 2 weeks of the study, two placebo patients (4%) stopped their study medication, compared with 20 sucralfate patients (40%). This was related to substantially increased incidences of gastrointestinal toxicity (58% of sucralfate patients v 14% of placebo patients; P > .0001). There was no substantial benefit from the sucralfate in terms of esophagitis scores. CONCLUSION This oral sucralfate solution does not appear to inhibit radiation-induced esophagitis and is associated with disagreeable gastrointestinal side effects in this patient population.
APA, Harvard, Vancouver, ISO, and other styles
14

&NA;. "Sucralfate." Reactions Weekly &NA;, no. 438 (1993): 11. http://dx.doi.org/10.2165/00128415-199304380-00043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

&NA;. "Sucralfate." Reactions Weekly &NA;, no. 549 (1995): 12. http://dx.doi.org/10.2165/00128415-199505490-00029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

&NA;. "Sucralfate." Reactions Weekly &NA;, no. 480 (1993): 12. http://dx.doi.org/10.2165/00128415-199304800-00056.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

&NA;. "Sucralfate." Reactions Weekly &NA;, no. 619 (1996): 10. http://dx.doi.org/10.2165/00128415-199606190-00027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Dallwig, Becky. "Sucralfate." Journal of Exotic Pet Medicine 19, no. 1 (2010): 101–4. http://dx.doi.org/10.1053/j.jepm.2010.01.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Marks, I. N. "Sucralfate." Journal of Clinical Gastroenterology 9 (1987): 18–22. http://dx.doi.org/10.1097/00004836-198709011-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Oates, John A., Alastair J. J. Wood, and Denis M. McCarthy. "Sucralfate." New England Journal of Medicine 325, no. 14 (1991): 1017–25. http://dx.doi.org/10.1056/nejm199110033251407.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

&NA;. "Sucralfate." Reactions Weekly &NA;, no. 377 (1991): 11. http://dx.doi.org/10.2165/00128415-199103770-00054.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

&NA;. "Sucralfate." Reactions Weekly &NA;, no. 407 (1992): 11. http://dx.doi.org/10.2165/00128415-199204070-00041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

&NA;. "Sucralfate." Reactions Weekly &NA;, no. 412 (1992): 11. http://dx.doi.org/10.2165/00128415-199204120-00041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Freitas, Bruna Zini de Paula, José Aires Pereira, Danilo Toshio Kanno, Paula Cristina Steffen Novelli, Fábio Guilherme Campos, and Carlos Augusto Real Martinez. "AVALIAÇÃO DOS EFEITOS PROTETORES DO SUCRALFATO NO CONTEÚDO TECIDUAL DAS PROTEÍNAS E‐CADERINA, B‐CATENINA, CLAUDINA‐3, OCLUDINA, ATIVIDADE ANTI‐INFLAMATÓRIA E ANTIOXIDANTE NA MUCOSA CÓLICA DESPROVIDA DE TRÂNSITO INTESTINAL." Journal of Coloproctology 38 (October 2018): 155–56. http://dx.doi.org/10.1016/j.jcol.2018.08.332.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Hall, Thomas G., Paul G. Cuddy, Cynthia J. Glass, and Srikumaran Melethil. "Effect of Sucralfate on Phenytoin Bioavailability." Drug Intelligence & Clinical Pharmacy 20, no. 7-8 (1986): 607–11. http://dx.doi.org/10.1177/106002808602000726.

Full text
Abstract:
The mechanism of action of the antiulcer agent, sucralfate, involves drug binding to proteins, pepsin, and bile salts. The potential for sucralfate to bind to, and inhibit the oral absorption of, concurrently-administered drugs has been studied for very few agents. Phenytoin bioavailability was studied following a single dose of phenytoin 500 mg po in nine normal subjects during a control period and when given with sucralfate. Area under the serum concentration-time curve was compared at 48 hours (AUC48) and 120 hours (AUC120) using observed and extrapolated data. The phenytoin AUC48 was reduced from [Formula: see text], and the phenytoin AUC120 was reduced from 200.5 ± [Formula: see text], when sucralfate was administered. Because AUC comparisons for drugs with nonlinear elimination kinetics may reflect changes in rate, as well as extent, of absorption, these small changes in AUC may not reflect a change in the fraction of dose absorbed. However, our results suggest that sucralfate does affect phenytoin absorption. Further studies may be useful in determining the precise nature and clinical importance of this interaction.
APA, Harvard, Vancouver, ISO, and other styles
26

Watanabe, Koichiro, Kazunari Murakami, Ryugo Sato, et al. "Effect of Sucralfate on Antibiotic Therapy for Helicobacter pylori Infection in Mice." Antimicrobial Agents and Chemotherapy 48, no. 12 (2004): 4582–88. http://dx.doi.org/10.1128/aac.48.12.4582-4588.2004.

Full text
Abstract:
ABSTRACT It has been documented that sucralfate, a basic aluminum salt, enhances the efficacies of antibiotics against Helicobacter pylori, resulting in eradication rates comparable to those associated with the use of proton pump inhibitors. However, its mechanism of action remains unclear. The aim of the present study was to investigate sucralfate's ability to complement antibiotic treatment of H. pylori infection in vivo. Four weeks following induced H. pylori infection, clarithromycin (CAM) and amoxicillin (AMPC) were administered orally to C57BL/6 mice for 5 days, both with and without sucralfate or lansoprazole. When sucralfate was concurrently given with CAM and AMPC at the maximum noninhibitory doses for the treatment of H. pylori infection, the bacterial clearance rates were comparable to those achieved by treatment with lansoprazole plus those antibiotics. The results of pharmacokinetic studies showed that lansoprazole delayed gastric clearance and accelerated the absorption of CAM, whereas sucralfate suppressed both gastric clearance and absorption. AMPC was undetectable in all samples. Scanning electron microscopy with a microscope to which a energy dispersive spectrometer was attached revealed that aluminum-containing aggregated substances coated the mucosa surrounding H. pylori in mice receiving sucralfate plus antibiotics, whereas the gastric surface and pits where H. pylori had attached were clearly visible in mice receiving lansoprazole plus antibiotics. The addition of sucralfate to the antibiotic suspension resulted in a more viscous mixture that bound to the H. pylori-infected mucosa and that inhibited the loss of CAM bioavailability in the acidic environment. Sucralfate delays gastric clearance of CAM and physically captures H. pylori through the creation of an adherent mucus, which leads to bacterial clearance.
APA, Harvard, Vancouver, ISO, and other styles
27

Watanakunakorn, Paul W., Chatrchai Watanakunakorn, and John Hazy. "Risk Factors Associated With Clostridium difficile Diarrhea in Hospitalized Adult Patients: A Case-Control Study—Sucralfate Ingestion is Not a Negative Risk Factor." Infection Control & Hospital Epidemiology 17, no. 4 (1996): 232–35. http://dx.doi.org/10.1017/s0195941700003817.

Full text
Abstract:
AbstractObjectives:To assess risk factors associated with Clostridium difficile diarrhea in hospitalized adult patients, and to test the hypothesis that sucralfate ingestion is associated with nondetection of C difficile cytotoxin in stool specimens.Design:A retrospective case-control study of hospitalized adult patients who had stool specimens assayed for C difficile cytotoxin. For each patient who had positive C difficile cytotoxin, a patient who had negative C difficile cytotoxin was used as a control. The study period was January to December 1993.Setting:A community teaching hospital affiliated with a medical school in northeastern Ohio.Results:There were 91 case patients and 91 control patients. Cephalosporin exposure was identified as a risk factor in patients with C difficile diarrhea. The number of patients who had sucralfate ingestion was comparable in both groups of patients.Conclusions:Administration of cephalosporins was identified as a risk factor in patients with C difficile diar-rhea. We were not able to confirm a recent report of the association between ingestion of sucralfate and nondetection of C difficile cytotoxin in stool specimens. Our findings suggest that sucralfate ingestion is not associated with nondetection of C difficile cytotoxin in stool specimens. Assay of C difficile cytotoxin in stool specimens remains a valid method of diagnosing C difficile diarrhea, even in patients who ingest sucralfate.
APA, Harvard, Vancouver, ISO, and other styles
28

Guslandi, M., M. Sorghi, A. Foppa, PC Braga, and A. Tittobello. "Effect of a Gel Formulation of Sucralfate on Gastric Microcirculation." Journal of International Medical Research 21, no. 1 (1993): 47–50. http://dx.doi.org/10.1177/030006059302100105.

Full text
Abstract:
Dyspeptic patients ( n = 12) with endoscopic signs of chronic gastritis were treated orally for 28 days with a new gel formulation of sucralfate at a dose of 1 g twice daily. Before and after treatment, gastric blood flow was assessed during endoscopy by means of laser Doppler flowmetry. The sucralfate gel promoted a significant increase ( P < 0.001) in blood perfusion in all patients, restoring normal levels of gastric microcirculation. The results are consistent with observations in animals, suggesting that the mechanisms responsible for the gastroprotective and therapeutic properties of sucralfate include enhancement of mucosal blood flow.
APA, Harvard, Vancouver, ISO, and other styles
29

&NA;. "Antacids/sucralfate." Reactions Weekly &NA;, no. 446 (1993): 5. http://dx.doi.org/10.2165/00128415-199304460-00012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

&NA;. "Sucralfate interaction." Reactions Weekly &NA;, no. 427 (1992): 11. http://dx.doi.org/10.2165/00128415-199204270-00049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

&NA;. "Sucralfate interaction." Reactions Weekly &NA;, no. 364 (1991): 11. http://dx.doi.org/10.2165/00128415-199103640-00056.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

&NA;. "Cimetidine/sucralfate." Reactions Weekly &NA;, no. 497 (1994): 6. http://dx.doi.org/10.2165/00128415-199404970-00016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Bronner, Mark H. "Sucralfate suspension." Gastrointestinal Endoscopy 31, no. 5 (1985): 353. http://dx.doi.org/10.1016/s0016-5107(85)72230-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

VASQUEZ, TONY E., HAROLD T. PRETORIUS, and GILBERT GREENSPAN. "Radiolabeled sucralfate." Nuclear Medicine Communications 8, no. 5 (1987): 327–34. http://dx.doi.org/10.1097/00006231-198705000-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Sandberg, Alan, Simmy Bank, and Victoria Kranz. "Sucralfate effects." Digestive Diseases and Sciences 34, no. 6 (1989): 959–60. http://dx.doi.org/10.1007/bf01540286.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Alkhateep, Yahia, and Abdelmieniem Fareed. "Double blinded randomized placebo-controlled comparative study between sucralfate ointment and lidocaine ointment after Milligan Morgan hemorrhoidectomy." International Surgery Journal 4, no. 12 (2017): 3822. http://dx.doi.org/10.18203/2349-2902.isj20175111.

Full text
Abstract:
Background: Post haemorrhoidectomy pain and delayed wound healing are the most annoying drawbacks to the patients and the surgeons. Topical application of sucralfate or lidocaine may help in reducing postoperative pain and promoting wound healing after Milligan Morgan hemorrhoidectomy.Methods: This study was designed as a single-center double blinded randomized placebo controlled trial at the Department of general Surgery Menoufia University, immediately after Milligan Morgan Hemorrhoidectomy, a total of 150 patients were randomly assigned to receive either 10% Sucralfate ointment, 5% lidocaine ointment or placebo ointment (control group). The primary outcome measure was pain intensity measured by a visual analogue scale at different time points after hemorrhoidectomy and the secondary outcome measure was wound healing.Results: There was no significant difference in age, gender, and number of excised hemorrhoid piles between the two groups. At the 1st ,3rd and 7th days after surgery pain intensity was significantly lower in sucralfate group (4.18±0.82, 3.92±0.72, 3.56±0.67) when compared to lidocaine group (5.06±1.11, 4.70±0.84, 3.93±0.75) and placebo group (6.17±1.26, 5.42±0.98, 4.55±0.84). At the 21st and 28th days no significant difference in pain intensity between groups (p > 0.05) with better wound healing in sucralfate group (P<0.05).Conclusions: Sucralfate was able to reduce the acute postoperative pain and improve wound healing after hemorrhoidectomy, local anesthetic lidocaine could help in pain control but without effect on healing.
APA, Harvard, Vancouver, ISO, and other styles
37

Giorgi, Francesca, Romeo Bascioni, Giorgio De Signoribus, and Franco Di Saverio. "Sucralfate Prophylaxis of Fluorouracil-Induced Stomatitis." Tumori Journal 82, no. 6 (1996): 585–87. http://dx.doi.org/10.1177/030089169608200614.

Full text
Abstract:
Aims and Background Various attempts have been made to prevent 5-fluorouracil-induced stomatitis, with unsatisfactory results. Sucralfate is an aluminum hydroxide, complex of sulfated sucrose commonly used in the treatment of gastroduodenal ulcers. We used the compound in a phase II study to reduce and minimize the stomatotoxicity of 5-fluorouracil chemotherapy administered in a multiple-day schedule. Methods Fifty-two patients entered the study, and 129 cycles of chemotherapy were evaluated. Seven patients refused sucralfate rinses for taste intolerance. Results A low level of stomatotoxicity was recorded: grade 2 stomatitis was observed after 14 cycles (10.8%) and grade 3 after 3 cycles (2.3%). Conclusions Sucralfate administration could have a role in the prevention of 5-fluorouracil-induced stomatitis.
APA, Harvard, Vancouver, ISO, and other styles
38

Miura, Mauricio Schreiner, Catia Saleh, Marina de Andrade, Melina Assmann, Marcio Ayres, and José Faibes Lubianca Neto. "Topical Sucralfate in Post-Adenotonsillectomy Analgesia in Children." Otolaryngology–Head and Neck Surgery 141, no. 3 (2009): 322–28. http://dx.doi.org/10.1016/j.otohns.2009.05.032.

Full text
Abstract:
OBJECTIVES: Tonsillectomy, with or without adenoidectomy, is one of the most common surgical procedures in pediatric otolaryngology. Despite its relative simplicity, pain is the main cause of morbidity in the postoperative period. We determined the effect of topical sucralfate on reduction of oropharyngeal pain in children submitted to adenotonsillectomy. Secondary outcomes were otalgia, analgesic use, type of diet, secondary bleeding, vomiting, fever, and weight loss. STUDY DESIGN: Double-blind, randomized clinical trial. SETTING: Tertiary hospital. SUBJECTS AND METHODS: Eighty-two children of both sexes between four and 12 years old submitted to adenotonsillectomy were evaluated. They were allocated to receive topical sucralfate or placebo in intraoperative and postoperative periods four times a day for five days. Pain was measured through faces pain scale. RESULTS: Reduction in oropharyngeal pain was significant with use of sucralfate during five days of evaluation (mean, 95% confidence interval, and P value); day 1: 2.05, 1.53–2.58, P = 0.000; day 2: 2.1, 1.51–2.70, P = 0.001; day 3: 1.44, 0.88–1.99, P = 0.003; day 4: 1.13, 0.58–1.55, P = 0.027; day 5: 0.67, 0.26–1.04, P = 0.021). There was no difference in secondary outcomes. CONCLUSION: We found beneficial effect of use of sucralfate in reduction of oropharyngeal pain in the postoperative period of adenotonsillectomy. However, topical sucralfate does not have a potent effect to the point of being utilized as a single analgesic treatment. Because it is simple, safe, tolerated, and low-cost, it is an important tool as adjuvant treatment of post-tonsillectomy pain.
APA, Harvard, Vancouver, ISO, and other styles
39

Dogra, Richa, S. P. Tyagi, and Amit Kumar. "Efficacy of Seabuckthorn (Hippophae rhamnoides) Oilvis-a-visOther Standard Drugs for Management of Gastric Ulceration and Erosions in Dogs." Veterinary Medicine International 2013 (2013): 1–11. http://dx.doi.org/10.1155/2013/176848.

Full text
Abstract:
The study was conducted on 20 adult healthy medium-sized mongrel dogs. Injection of dexamethasone @ 1 mg/kg, IV, b.i.d., was administered to create gastric ulcerations and erosions. Thereafter all the animals were randomly divided into 5 equal treatment groups. Animals of groups I, II, III, IV, and V were treated with oral administration of lansoprazole @ 1.5 mg/kg, sucralfate @ 1 g/animal, misoprostol @ 10 µg/kg, famotidine @ 1 mg/kg, and Seabuckthorn seed oil @ 5 mL/animal, twice a day, respectively. Gastroendoscopically, complete healing of GUE lesions was earliest in Seabuckthorn- (SBT-) oil-treated group (7.5±0.87) followed by famotidine (8.25±1.44), lansoprazole (9.00±1.23), misoprostol (10.50±1.50), and sucralfate (13.50±0.87), respectively. A marked improvement in appetite was observed in all animals. Melena was continued till day 3 in SBT group, day 6 in lansoprazole- and famotidine-treated animals, and day 9 in sucralfate and misoprostol group animals. Fecal occult blood test was positive in all animals till there was endoscopic evidence of gastric bleeding. Hematological parameters improved markedly towards the end of the study. Serum biochemical parameters remained within normal physiological limits throughout the study. It is concluded that Seabuckthorn oil was the best therapeutic agent for dexamethasone-induced GUE in dogs followed by famotidine, lansoprazole, misoprostol, and sucralfate.
APA, Harvard, Vancouver, ISO, and other styles
40

Gargiullo, Robert J. "Liquid Chromatographic Determination of Sucralfate in Dental Cream." Journal of AOAC INTERNATIONAL 75, no. 5 (1992): 809–11. http://dx.doi.org/10.1093/jaoac/75.5.809.

Full text
Abstract:
Abstract A simple, rapid liquid chromatographic method is described for quantitative determination of sucralfate in dental cream. Analyses were performed on a weak anion exchange column with 0.6M ammonium sulfate-0.005M tetrabutylammonium hydrogen sulfate as the mobile phase and refractive index detection. The method was linear over a range of 0.0 to 20.0% sucralfate in dental cream. The coefficient of variation was 3.2%. Standard recoveries were concentration dependent and ranged from 97.2 to 104.9%.
APA, Harvard, Vancouver, ISO, and other styles
41

Siddiqui, Atif Hafeez, Danish ur Rahim, Irfan Ahmed Shaikh, Iqbal A. Muhammad Khayani, Vijay Kumar Khatri, and Subata Siddiqui. "Efficacy of Sucralfate in alleviation of postoperative morbidity after tonsillectomy." Professional Medical Journal 27, no. 03 (2020): 618–24. http://dx.doi.org/10.29309/tpmj/2020.27.03.3815.

Full text
Abstract:
Objectives: Despite of the therapeutic advancement, post-tonsillectomy pain is one of the most commonly observed morbidities associated with this surgical procedure which in turn highlights the need for appropriate analgesic consumption that assures safety and efficacy. Through this study our basic motive was to evaluate the sucralfate efficacy in the management of post-tonsillectomy symptoms during the first week of the surgery. Study Design: An Interventional, Quasi Experimental, (double-blind), purposive study. Setting: Department of Otorhinolaryngology and Head and Neck Surgery, Dow University of Health Sciences & Civil Hospital Karachi. Period: From January to June 2018. Material & Methods: One hundred and forty tonsillectomy patients of both genders between the age group of 7 to 35 years were randomly included in the study and categorized into 2 groups i.e. trial (Sucralfate group; Group A) and control (Pyodine group; Group B) with 70 patients in each group. The patients in group A were recommended to gargle with sucralfate suspension 4 times a day while following the same procedure except the group B interventional product was replaced with Pyodine mouth wash. The post-operative symptoms and secondary outcomes including pain, otalgia, odynophagia, analgesic requirements, slough shedding, bleeding and other associated side-effects were monitored. Pain, otalgia and odynophagia were assessed using the universal pain assessment tool (UPAT) while the secondary outcomes through a scoring system generated internally. Results: It is revealed from the study results that there was significant decrease in the throat pain and odynophagia in group A from 3rd to 7th post-tonsillectomy day (p < 0.05); while the results were not very significant for otalgia. The same could be applied for other secondary outcomes i.e. the analgesic requirement greatly decreased in patients given sucralfate presenting faster recovery. Moreover, early return to normal diet was observed for the patients treated with sucralfate. No serious adverse effects observed among the patients both groups. Conclusion: Sucralfate can be recommended as the first choice of treatment for the management of post-tonsillectomy symptoms on the basis of its efficiency in treating pain and other symptoms and hence providing maximum safety.
APA, Harvard, Vancouver, ISO, and other styles
42

Lee, L. J., B. Hafkin, I. D. Lee, J. Hoh, and R. Dix. "Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects." Antimicrobial Agents and Chemotherapy 41, no. 10 (1997): 2196–200. http://dx.doi.org/10.1128/aac.41.10.2196.

Full text
Abstract:
The effects of food and sucralfate on the pharmacokinetics of levofloxacin following the administration of a single 500-mg oral dose were investigated in a randomized, three-way crossover study with young healthy subjects (12 males and 12 females). Levofloxacin was administered under three conditions: fasting, fed (immediately after a standardized high-fat breakfast), and fasting with sucralfate given 2 h following the administration of levofloxacin. The concentrations of levofloxacin in plasma and urine were determined by high-pressure liquid chromatography. By noncompartmental methods, the maximum concentration of drug in serum (Cmax), the time to Cmax (Tmax), the area under the concentration-time curve (AUC), half-life (t1/2), clearance (CL/F), renal clearance (CLR), and cumulative amount of levofloxacin in urine (Ae) were estimated. The individual profiles of the drug concentration in plasma showed little difference among the three treatments. The only consistent effect of the coadministration of levofloxacin with a high-fat meal for most subjects was that levofloxacin absorption was delayed and Cmax was slightly reduced (Tmax, 1.0 and 2.0 h for fasting and fed conditions, respectively [P = 0.002]; Cmax, 5.9 +/- 1.3 and 5.1 +/- 0.9 microg/ml [90% confidence interval = 0.79 to 0.94] for fasting and fed conditions, respectively). Sucralfate, which was administered 2 h after the administration of levofloxacin, appeared to have no effect on levofloxacin's disposition compared with that under the fasting condition. Mean values of Cmax and AUC from time zero to infinity were 6.7 +/- 3.2 microg/ml and 47.9 +/- 8.4 microg x h/ml, respectively, following the administration of sucralfate compared to values of 5.9 +/- 1.3 microg/ml and 50.5 +/- 8.1 microg x h/ml, respectively, under fasting conditions. The mean t1/2, CL/F, CLR, and Ae values were similar among all three treatment groups. In conclusion, the absorption of levofloxacin was slightly delayed by food, although the overall bioavailability of levofloxacin following a high-fat meal was not altered. Finally, sucralfate did not alter the disposition of levofloxacin when sucralfate was given 2 h after the administration of the antibacterial agent, thus preventing a potential drug-drug interaction.
APA, Harvard, Vancouver, ISO, and other styles
43

Loprinzi, C. L., C. Ghosh, J. Camoriano, et al. "Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy." Journal of Clinical Oncology 15, no. 3 (1997): 1235–38. http://dx.doi.org/10.1200/jco.1997.15.3.1235.

Full text
Abstract:
PURPOSE Stomatitis is a major dose-limiting toxicity of bolus fluorouracil (5FU)-based chemotherapy regimens, despite the use of oral cryotherapy. Pursuant to preliminary data that suggested a sucralfate oral solution could alleviate chemotherapy-induced oral mucositis, we developed a prospective trial to test this contention. PATIENTS AND METHODS A phase III, double-blind, placebo-controlled clinical trial was designed. Patients were entered onto the study at the time of the first cycle of 5FU-based chemotherapy. All patients received oral cryotherapy for 30 minutes with each dose of 5FU. In addition, each patient was randomized to receive either a sucralfate solution or a placebo solution to be used if they developed mouth tenderness or mouth sores. The study solution was to be used four times daily for 7 days starting on the first day of mouth tenderness or mouth sores. Stomatitis scores were determined by health care providers and by patients themselves. RESULTS There was a total of 131 assessable patients entered onto this trial, 50 of whom developed mucositis and used the study medication (27 sucralfate and 23 placebo). There was no suggestion of any difference in stomatitis severity or duration on either protocol arm. CONCLUSION The resultant data from this clinical trial did not support the prestudy hypothesis that sucralfate would be beneficial for the treatment of 5FU-induced stomatitis.
APA, Harvard, Vancouver, ISO, and other styles
44

&NA;. "Sucralfate/enteral feeding." Reactions Weekly &NA;, no. 459 (1993): 12. http://dx.doi.org/10.2165/00128415-199304590-00059.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Funch-Jensen, P., E. Skoubo Kristensen, A. Kruse, F. Hanberg Soerensen, and E. Amdrup. "Sucralfate in Gastritis." Scandinavian Journal of Gastroenterology 22, sup127 (1987): 93–96. http://dx.doi.org/10.3109/00365528709090958.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Parrish, Richard H., Brenda Waller, and B. G. Gondalia. "Sucralfate—Warfarin Interaction." Annals of Pharmacotherapy 26, no. 7-8 (1992): 1015–16. http://dx.doi.org/10.1177/106002809202600733.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Braverman, Steven E., and Mark T. Marino. "Sucralfate—Warfarin Interaction." Drug Intelligence & Clinical Pharmacy 22, no. 11 (1988): 913. http://dx.doi.org/10.1177/106002808802201121.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

&NA;. "Sucralfate/aluminium hydroxide." Reactions Weekly &NA;, no. 371 (1991): 11–12. http://dx.doi.org/10.2165/00128415-199103710-00056.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Shepherd, K. E., C. S. Faulkner, and J. C. Leiter. "ALKALINE SUCRALFATE ASPIRATIONS." Anesthesiology 81, SUPPLEMENT (1994): A315. http://dx.doi.org/10.1097/00000542-199409001-00314.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

&NA;. "Ciprofloxacin/metronidazole/sucralfate." Reactions Weekly &NA;, no. 1384 (2012): 19. http://dx.doi.org/10.2165/00128415-201213840-00069.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography